<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d375" origId="Aminocaproic Acid"><sentence id="DrugDDI.d375.s0" origId="s0" text="Drug Laboratory Test Interactions? Prolongation of the template bleeding time has been reported during continuous intravenous infusion of AMICAR at dosages exceeding 24 g/day."><entity id="DrugDDI.d375.s0.e0" origId="s0.p0" charOffset="0-4" type="drug" text="Drug"/><entity id="DrugDDI.d375.s0.e1" origId="s0.p6" charOffset="138-144" type="drug" text="AMICAR"/><pair id="DrugDDI.d375.s0.p0" e1="DrugDDI.d375.s0.e0" e2="DrugDDI.d375.s0.e1" interaction="false"/></sentence><sentence id="DrugDDI.d375.s1" origId="s1" text="Platelet function studies in these patients have not demonstrated any significant platelet dysfunction."/><sentence id="DrugDDI.d375.s2" origId="s2" text="However, in vitro studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) EACA inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner."><entity id="DrugDDI.d375.s2.e0" origId="s2.p36" charOffset="126-134" type="drug" text="collagen"/><entity id="DrugDDI.d375.s2.e1" origId="s2.p43" charOffset="218-228" type="drug" text="fibrinogen"/><pair id="DrugDDI.d375.s2.p0" e1="DrugDDI.d375.s2.e0" e2="DrugDDI.d375.s2.e1" interaction="false"/></sentence><sentence id="DrugDDI.d375.s3" origId="s3" text="Following a 10 g bolus of AMICAR, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained."><entity id="DrugDDI.d375.s3.e0" origId="s3.p48" charOffset="26-32" type="drug" text="AMICAR"/></sentence><sentence id="DrugDDI.d375.s4" origId="s4" text="The concentration of AMICAR necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL."><entity id="DrugDDI.d375.s4.e0" origId="s4.p59" charOffset="21-27" type="drug" text="AMICAR"/></sentence><sentence id="DrugDDI.d375.s5" origId="s5" text="Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL."/><sentence id="DrugDDI.d375.s6" origId="s6" text="Thus, concentrations which have been obtained in vivo clinically in patients with normal renal function are considerably lower than the in vitro concentrations found to induce abnormalities in platelet function tests."/><sentence id="DrugDDI.d375.s7" origId="s7" text="However, higher plasma concentrations of AMICAR may occur in patients with severe renal failure.?"><entity id="DrugDDI.d375.s7.e0" origId="s7.p101" charOffset="41-47" type="drug" text="AMICAR"/></sentence></document>